Copyright Reports & Markets. All rights reserved.

Global Peptide Cancer Vaccine Market Insights and Forecast to 2027

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Peptide Cancer Vaccine Product Introduction
  • 1.2 Market by Regions
    • 1.2.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Regions
    • 1.4.2 USA
    • 1.4.3 Europe
    • 1.2.4 Japan
    • 1.2.5 China
    • 1.2.6 South America
    • 1.2.7 Other
  • 1.3 Market by Application
    • 1.3.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Application
    • 1.3.2 Breast Cancer
    • 1.3.3 Lung Cancer
    • 1.3.4 Melanoma
    • 1.3.5 Prostate Cancer
    • 1.3.6 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Peptide Cancer Vaccine Sales Estimates and Forecasts 2016-2027
  • 2.2 Global Peptide Cancer Vaccine Revenue Estimates and Forecasts 2016-2027
  • 2.3 Global Peptide Cancer Vaccine Revenue by Region: 2016 VS 2021 VS 2027
  • 2.4 Global Top Peptide Cancer Vaccine Regions by Sales
    • 2.4.1 Global Top Peptide Cancer Vaccine Regions by Sales (2016-2021)
    • 2.4.2 Global Top Peptide Cancer Vaccine Regions by Sales (2022-2027)
  • 2.5 Global Top Peptide Cancer Vaccine Regions by Revenue
    • 2.5.1 Global Top Peptide Cancer Vaccine Regions by Revenue (2016-2021)
    • 2.5.2 Global Top Peptide Cancer Vaccine Regions by Revenue (2022-2027)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Peptide Cancer Vaccine Sales by Manufacturers
    • 3.1.1 Global Top Peptide Cancer Vaccine Manufacturers by Sales (2016-2021)
    • 3.1.2 Global Top Peptide Cancer Vaccine Manufacturers Market Share by Sales (2016-2021)
    • 3.1.3 Global Top 10 and Top 5 Companies by Peptide Cancer Vaccine Sales in 2020
  • 3.2 Global Peptide Cancer Vaccine Revenue by Manufacturers
    • 3.2.1 Global Top Peptide Cancer Vaccine Manufacturers by Revenue (2016-2021)
    • 3.2.2 Global Top Peptide Cancer Vaccine Manufacturers Market Share by Revenue (2016-2021)
    • 3.2.3 Global Top 10 and Top 5 Companies by Peptide Cancer Vaccine Revenue in 2020
  • 3.3 Global Peptide Cancer Vaccine Sales Price by Manufacturers
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Peptide Cancer Vaccine Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Peptide Cancer Vaccine Sales by Regions
    • 4.1.1 Global Peptide Cancer Vaccine Historical Sales by Regions (2016-2021)
    • 4.1.2 Global Peptide Cancer Vaccine Forecasted Sales by Regions (2022-2027)
    • 4.1.3 Global Peptide Cancer Vaccine Sales Market Share by Regions (2016-2027)
  • 4.2 Global Peptide Cancer Vaccine Revenue by Regions
    • 4.2.1 Global Peptide Cancer Vaccine Historical Revenue by Regions (2016-2021)
    • 4.2.2 Global Peptide Cancer Vaccine Forecasted Revenue by Regions (2022-2027)
    • 4.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Regions (2016-2027)
  • 4.3 Global Peptide Cancer Vaccine Price by Regions
    • 4.3.1 Global Peptide Cancer Vaccine Price by Regions (2016-2021)
    • 4.3.2 Global Peptide Cancer Vaccine Price Forecast by Regions (2022-2027)

5 Market Size by Application

  • 5.1 Global Peptide Cancer Vaccine Sales by Application
    • 5.1.1 Global Peptide Cancer Vaccine Historical Sales by Application (2016-2021)
    • 5.1.2 Global Peptide Cancer Vaccine Forecasted Sales by Application (2022-2027)
    • 5.1.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2016-2027)
  • 5.2 Global Peptide Cancer Vaccine Revenue by Application
    • 5.2.1 Global Peptide Cancer Vaccine Historical Revenue by Application (2016-2021)
    • 5.2.2 Global Peptide Cancer Vaccine Forecasted Revenue by Application (2022-2027)
    • 5.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2016-2027)
  • 5.3 Global Peptide Cancer Vaccine Price by Application
    • 5.3.1 Global Peptide Cancer Vaccine Price by Application (2016-2021)
    • 5.3.2 Global Peptide Cancer Vaccine Price Forecast by Application (2022-2027)

6 North America

  • 6.1 North America Peptide Cancer Vaccine Market Size by Regions
    • 6.1.1 North America Peptide Cancer Vaccine Sales by Regions (2016-2027)
    • 6.1.2 North America Peptide Cancer Vaccine Revenue by Regions (2016-2027)
  • 6.2 North America Peptide Cancer Vaccine Market Size by Application
    • 6.2.1 North America Peptide Cancer Vaccine Sales by Application (2016-2027)
    • 6.2.2 North America Peptide Cancer Vaccine Revenue by Application (2016-2027)
  • 6.3 North America Peptide Cancer Vaccine Market Size by Country
    • 6.3.1 North America Peptide Cancer Vaccine Sales by Country (2016-2027)
    • 6.3.2 North America Peptide Cancer Vaccine Revenue by Country (2016-2027)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Peptide Cancer Vaccine Market Size by Regions
    • 7.1.1 Europe Peptide Cancer Vaccine Sales by Regions (2017-2027)
    • 7.1.2 Europe Peptide Cancer Vaccine Revenue by Regions (2017-2027)
  • 7.2 Europe Peptide Cancer Vaccine Market Size by Application
    • 7.2.1 Europe Peptide Cancer Vaccine Sales by Application (2017-2027)
    • 7.2.2 Europe Peptide Cancer Vaccine Revenue by Application (2017-2027)
  • 7.3 Europe Peptide Cancer Vaccine Market Size by Country
    • 7.3.1 Europe Peptide Cancer Vaccine Sales by Country (2017-2027)
    • 7.3.2 Europe Peptide Cancer Vaccine Revenue by Country (2017-2027)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Peptide Cancer Vaccine Market Size by Regions
    • 8.1.1 Asia Pacific Peptide Cancer Vaccine Sales by Regions (2018-2027)
    • 8.1.2 Asia Pacific Peptide Cancer Vaccine Revenue by Regions (2018-2027)
  • 8.2 Asia Pacific Peptide Cancer Vaccine Market Size by Application
    • 8.2.1 Asia Pacific Peptide Cancer Vaccine Sales by Application (2018-2027)
    • 8.2.2 Asia Pacific Peptide Cancer Vaccine Revenue by Application (2018-2027)
  • 8.3 Asia Pacific Peptide Cancer Vaccine Market Size by Region
    • 8.3.1 Asia Pacific Peptide Cancer Vaccine Sales by Region (2018-2027)
    • 8.3.2 Asia Pacific Peptide Cancer Vaccine Revenue by Region (2018-2027)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America Peptide Cancer Vaccine Market Size by Regions
    • 9.1.1 Latin America Peptide Cancer Vaccine Sales by Regions (2019-2027)
    • 9.1.2 Latin America Peptide Cancer Vaccine Revenue by Regions (2019-2027)
  • 9.2 Latin America Peptide Cancer Vaccine Market Size by Application
    • 9.2.1 Latin America Peptide Cancer Vaccine Sales by Application (2019-2027)
    • 9.2.2 Latin America Peptide Cancer Vaccine Revenue by Application (2019-2027)
  • 9.3 Latin America Peptide Cancer Vaccine Market Size by Country
    • 9.3.1 Latin America Peptide Cancer Vaccine Sales by Country (2019-2027)
    • 9.3.2 Latin America Peptide Cancer Vaccine Revenue by Country (2019-2027)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

6 Middle East and Africa

  • 6.1 Middle East and Africa Peptide Cancer Vaccine Market Size by Regions
    • 6.1.1 Middle East and Africa Peptide Cancer Vaccine Sales by Regions (2016-2027)
    • 6.1.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Regions (2016-2027)
  • 6.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Application
    • 6.2.1 Middle East and Africa Peptide Cancer Vaccine Sales by Application (2016-2027)
    • 6.2.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Application (2016-2027)
  • 6.3 Middle East and Africa Peptide Cancer Vaccine Market Size by Country
    • 6.3.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2016-2027)
    • 6.3.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2016-2027)
    • 6.3.3 Turkey
    • 6.3.4 Saudi Arabia
    • 6.3.5 U.A.E

11 Company Profiles

  • 11.1 TapImmune
    • 11.1.1 TapImmune Corporation Information
    • 11.1.2 TapImmune Overview
    • 11.1.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 TapImmune Peptide Cancer Vaccine Product Description
    • 11.1.5 TapImmune Related Developments
  • 11.2 BrightPath Biotherapeutics
    • 11.2.1 BrightPath Biotherapeutics Corporation Information
    • 11.2.2 BrightPath Biotherapeutics Overview
    • 11.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.2.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Description
    • 11.2.5 BrightPath Biotherapeutics Related Developments
  • 11.3 Ultimovacs
    • 11.3.1 Ultimovacs Corporation Information
    • 11.3.2 Ultimovacs Overview
    • 11.3.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.3.4 Ultimovacs Peptide Cancer Vaccine Product Description
    • 11.3.5 Ultimovacs Related Developments
  • 11.4 Sellas
    • 11.4.1 Sellas Corporation Information
    • 11.4.2 Sellas Overview
    • 11.4.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.4.4 Sellas Peptide Cancer Vaccine Product Description
    • 11.4.5 Sellas Related Developments
  • 11.5 Boston Biomedical
    • 11.5.1 Boston Biomedical Corporation Information
    • 11.5.2 Boston Biomedical Overview
    • 11.5.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.5.4 Boston Biomedical Peptide Cancer Vaccine Product Description
    • 11.5.5 Boston Biomedical Related Developments
  • 11.6 Imugene
    • 11.6.1 Imugene Corporation Information
    • 11.6.2 Imugene Overview
    • 11.6.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.6.4 Imugene Peptide Cancer Vaccine Product Description
    • 11.6.5 Imugene Related Developments
  • 11.7 VAXON Biotech
    • 11.7.1 VAXON Biotech Corporation Information
    • 11.7.2 VAXON Biotech Overview
    • 11.7.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.7.4 VAXON Biotech Peptide Cancer Vaccine Product Description
    • 11.7.5 VAXON Biotech Related Developments
  • 11.8 Generex Biotechnology
    • 11.8.1 Generex Biotechnology Corporation Information
    • 11.8.2 Generex Biotechnology Overview
    • 11.8.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.8.4 Generex Biotechnology Peptide Cancer Vaccine Product Description
    • 11.8.5 Generex Biotechnology Related Developments
  • 11.9 OncoTherapy Science
    • 11.9.1 OncoTherapy Science Corporation Information
    • 11.9.2 OncoTherapy Science Overview
    • 11.9.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.9.4 OncoTherapy Science Peptide Cancer Vaccine Product Description
    • 11.9.5 OncoTherapy Science Related Developments
  • 11.10 Immatics
    • 11.10.1 Immatics Corporation Information
    • 11.10.2 Immatics Overview
    • 11.10.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.10.4 Immatics Peptide Cancer Vaccine Product Description
    • 11.10.5 Immatics Related Developments
  • 11.1 TapImmune
    • 11.1.1 TapImmune Corporation Information
    • 11.1.2 TapImmune Overview
    • 11.1.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 TapImmune Peptide Cancer Vaccine Product Description
    • 11.1.5 TapImmune Related Developments

12 Value Chain and Sales Channels Analysis

  • 12.1 Peptide Cancer Vaccine Value Chain Analysis
  • 12.2 Peptide Cancer Vaccine Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Peptide Cancer Vaccine Production Mode & Process
  • 12.4 Peptide Cancer Vaccine Sales and Marketing
    • 12.4.1 Peptide Cancer Vaccine Sales Channels
    • 12.4.2 Peptide Cancer Vaccine Distributors
  • 12.5 Peptide Cancer Vaccine Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Peptide Cancer Vaccine Industry Trends
  • 13.2 Peptide Cancer Vaccine Market Drivers
  • 13.3 Peptide Cancer Vaccine Market Challenges
  • 13.4 Peptide Cancer Vaccine Market Restraints

14 Key Findings in The Global Peptide Cancer Vaccine Study

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details

    Peptide Cancer Vaccine market is segmented by Regions, and by Application. Players, stakeholders, and other participants in the global Peptide Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Regions and by Application for the period 2016-2027.

    Segment by Regions
    USA
    Europe
    Japan
    China
    South America
    Other

    Segment by Application
    Breast Cancer
    Lung Cancer
    Melanoma
    Prostate Cancer
    Others

    By Company
    TapImmune
    BrightPath Biotherapeutics
    Ultimovacs
    Sellas
    Boston Biomedical
    Imugene
    VAXON Biotech
    Generex Biotechnology
    OncoTherapy Science
    Immatics
    ISA Pharmaceuticals

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia

    Buy now